Paris – 30thMay 2018 – Euronext today welcomes Voluntis, a company specialised in digital therapeutics, on its listing on Euronext’s regulated market in Paris.
Voluntis’ primary mission is to empower people suffering from chronic conditions to self-manage their treatments on a daily basis, thereby providing real-world outcomes. To do so, Voluntis develops and markets digital therapeutics, which personalise treatment and support patients in the day-to-day management of their condition. Its therapeutic solutions, which work in real time using digital clinical algorithms, provide patients with tailored recommendations via a mobile app and their care team with patient data via a web app. The latter enables the team to adjust treatment dosage and manage related symptoms to the patients’ needs. Voluntis’ digital therapeutics can enhance real-life treatment efficacy and patient adherence, addressing a major medico-economic challenge.
Voluntis was listed through the admission to trading on 30 May 2018 of the 7,567,661 shares making up its equity, comprising of 2,150,000 new shares issued under a Global Offering.
The admission and issue price was set at €14 per share. Market capitalisation was €105.9 million on the day of listing. The offering raised €30.1 million altogether.
“I’m delighted to announce that our initial public offering - a defining moment in Voluntis’ development - has been completed successfully on Euronext Paris. It will pave the way for our expansion, into the United States, where we plan to expand our sales coverage significantly. It will also consolidate our digital therapeutics portfolio, including the continued development of our proprietary multi-cancer solution. The funds we raised will boost our ability to complete the large-scale roll out of next-generation healthcare solutions that personalise treatment and support patients on a daily basis with the management of their illness”, commented Pierre Leurent, Chief Executive Officer and co-founder of Voluntis. “We wish to thank our longstanding shareholders, our partner Sanofi and our new shareholders for their participation in this fundraising.”
 The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.